ACUTE GRAFT VERSUS HOST DISEASE: A BRIEF REVIEW
Graft‐versus‐Host Disease (GvHD) is an important complication that can be observed after allogeneic hematopoietic stem cell transplantation (alloHSCT). Acute graft‐versus‐host disease (aGvHD) is seen after alloHSCT and the incidence of aGvHD is around 30-50 percent. aGvHD prophylaxis is essential in patients undergoing AlloHSCT. Initial therapy of aGvHD is steroids. Prognosis is poor in aGvHD not responding to steroid. In this article, pathobiology, clinical findings, prophylaxis and treatment of aGvHD will be summarized.